Terlipressin

Generic Name: Terlipressin

Brand Names: Terlivaz

Drug Type: Biotech

CAS Number: 14636-12-5

Unique Ingredient Identifier: 7Z5X49W53P

Background: Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.

Indication: Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.

Associated Conditions: Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension

Clinical Trials

The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Using Haemostatic Tourniquets:

Not Applicable

Completed

Conditions: Myoma

Interventions: Drug: Terlipressin

First Posted Date: 2022-02-16

Last Posted Date: 2024-06-25

Lead Sponsor: Wael Elbanna Clinic

Target Recruit Count: 99

Registration Number: NCT05242783

Locations: 🇪🇬
Wael El-Banna Clinic, Maadi, Cairo, Egypt

The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations

Not Applicable

Recruiting

Conditions: Myoma

Interventions: Drug: Terlipressin

First Posted Date: 2021-12-27

Last Posted Date: 2024-06-25

Lead Sponsor: Wael Elbanna Clinic

Target Recruit Count: 99

Registration Number: NCT05170230

Locations: 🇪🇬
Wael El Banna Clinic, Maadi, Egypt

The Effect of Intramyometrial Injection of Terlipressin Versus Intramyometrial Injection of Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations

Not Applicable

Recruiting

Conditions: Laparoscopic Myomectomy

Interventions: Drug: Terlipressin

First Posted Date: 2021-12-13

Last Posted Date: 2024-06-25

Lead Sponsor: Wael Elbanna Clinic

Target Recruit Count: 99

Registration Number: NCT05154279

Locations: 🇪🇬
Wael El Banna Clinic, Maadi, Egypt
🇪🇬
National Research center, Cairo, Egypt

ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.

Phase 3

Recruiting

Conditions: Hemoptysis

Interventions: Drug: Placebo
Drug: Tranexamic Acid 500 MG
Drug: Terlipressin

First Posted Date: 2021-07-14

Last Posted Date: 2024-05-03

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 315

Registration Number: NCT04961528

Locations: 🇫🇷
AP-HP, Hôpital Européen Georges Pompidou, Paris, France

Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock

Not Applicable

Completed

Conditions: Septic Shock

Interventions: Drug: Usual care
Drug: Terlipressin treatment

First Posted Date: 2021-07-01

Last Posted Date: 2021-07-01

Lead Sponsor: Southeast University, China

Target Recruit Count: 22

Registration Number: NCT04948372

Locations: 🇨🇳
Nanjing Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China

Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.

Not Applicable

Conditions: Liver Cirrhosis

Interventions: Drug: Terlipressin
Other: Standard of Care

First Posted Date: 2021-03-29

Last Posted Date: 2021-11-10

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 310

Registration Number: NCT04819568

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

Phase 3

Completed

Conditions: Hepatorenal Syndrome

Interventions: Drug: Terlipressin

First Posted Date: 2020-07-07

Last Posted Date: 2024-10-09

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 50

Registration Number: NCT04460560

Locations: 🇺🇸
Baylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Piedmont Healthcare, Inc, Atlanta, Georgia, United States

and more 4 locations